Our PDX panel furthermore confirmed the limited efficacy of the mTOR inhibitor everolimus currently used in clinical trials, despite the crucial role the PI3K/Akt/mTOR pathway in many GBM (13, 51). This evidence concerns the gene AKT1 and glioblastoma.